$ALAB

LAZAR JACK R sold $3.6M of ALAB

LAZAR JACK R sold 10,000 shares of Astera Labs, Inc. (ALAB) at an average of $355.17 ($339.56–$362.84, $3.55M total) across 18 trades on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LAZAR JACK R
Published Jun 9, 2026, 12:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALAB
Neutral
medium confidence
Mentioned
$ALAB
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The disclosure updates the insider activity record for ALAB, but the pre-arranged nature typically lowers interpretive weight for near-term price direction.

02

Market read

Traders may monitor whether insider selling persists, but this filing alone is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The article provides only the sale details; it does not state whether other insiders bought, whether the plan is part of a larger scheduled program, or whether there were concurrent company disclosures.

Relevance 5/10Novelty 5/10Timing: Filed June 8; transaction dated June 4.

Background

This is an SEC Form 4 insider transaction: a director’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$ALABNeutralMedium confidence
Context

Astera Labs director Lazar Jack R sold $3.55M of ALAB shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction may be muted unless accompanied by other negative company-specific news.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but it specifies a pre-arranged 10b5-1 plan and the article contains no new operational/financial catalyst.

Market effects

Minimal—single-company insider transaction with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with periods of valuation risk or personal liquidity needs; traders may still fade strength if selling cadence continues.

Key entities

  • Astera Labs, Inc.

    Company whose shares were sold by a director under a 10b5-1 plan.

  • Lazar Jack R

    Director who sold 10,000 ALAB shares (weighted avg ~$355.17) for ~$3.55M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALABMed

Astera Labs Stock Fell 9% in a Day as an OpenAI Revenue Report Hit Chip Stocks. Here’s Where the Stock Could Go by 2030

Astera Labs (ALAB) stock dropped 9.21% to $347.05 on October 8, following a broader chip sector sell-off triggered by OpenAI's lower-than-expected revenue report. The company launched Aries 7, its PCIe 7 signal conditioning portfolio. Despite a 23% rise in 2026 revenue forecasts to $1.91B, free cash flow fell 49.6% YoY to $67.21M, raising concerns. Analysts' target prices range from $390 to $850, with a potential total return of 146%.

$ALABMed

Why is Astera Labs stock sliding today?

Astera Labs (ALAB) stock dropped 5.0% after Zacks Research downgraded it from 'strong buy' to 'hold', following a 10% surge on S&P 500 inclusion speculation. Insider selling and high valuation also pressured the stock, with broader market declines adding to the downturn. Competitors like Marvell Technology intensify the competitive landscape. The stock remains sensitive to macroeconomic factors and analyst commentary.

$ALABHigh

Why is Astera Labs stock surging today?

Astera Labs (ALAB) stock surged 9.5% to $396.82, with traders anticipating its inclusion in the S&P 500. The company reported Q2 revenue of $392.4M, beating estimates, and guided Q3 revenue to $540M–$560M. Analysts, including Fubon, have upgraded the stock, with a $500 price target. The S&P 500 and Nasdaq each rose 0.7% today.

$ALABMed

ALAB Stock Holds Support As High Valuation Tests Traders

Astera Labs Inc. (ALAB) stock rose 6.54% due to strong AI infrastructure demand. The company reported $392.4M in quarterly revenue, $153.1M in net income, and $67.2M in free cash flow. ALAB trades at 127x earnings and 37x sales, with a strong balance sheet but high valuation concerns. Traders are watching key price levels around $262–$265 and $272–$275.

$ALABMed

ALAB Broadens Leo Portfolio: Can It Stay Ahead of MRVL & CRDO?

Astera Labs (ALAB) reported record Q2 2026 revenue growth, driven by AI connectivity products. The company expanded its Leo CXL memory controller portfolio, gaining hyperscaler traction. Q3 2026 revenue is expected between $540M and $560M. Competitors Marvell (MRVL) and Credo (CRDO) are also advancing in AI connectivity. ALAB shares rose 51.8% YTD, with a forward P/S of 16.16X.